Hematopoietic Stem Cell Transplantation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hematopoietic stem cell transplantation markets are expected to exhibit a CAGR of 7.6% during 2024-2034.
The hematopoietic stem cell transplantation market has been comprehensively analyzed in IMARC's new report titled "Hematopoietic Stem Cell Transplantation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hematopoietic stem cell transplantation (HSCT) refers to a medical procedure used to treat various conditions affecting the blood and immune system. This technique involves the replacement of damaged or destroyed bone marrow with healthy blood cells, including red blood cells, white blood cells, and platelets. It is broadly categorized as autologous, allogeneic, or syngeneic transplantation. Autologous HSCT involves using a patient's own stem cells for transplantation, whereas allogeneic HSCT relies on stem cells obtained from a donor, typically a family member or an unrelated donor with compatible tissue typing. In syngeneic transplantation, the donor and recipient are generally identical twins, although it can also be performed between other individuals who share a close genetic match. Various cell sources include bone marrow, umbilical cord blood, peripheral blood, or, rarely, fetal liver. In some cases, the patients might experience transplantation-related symptoms, such as nausea, vomiting, mouth sores or ulcers, diarrhea, abdominal pain, loss of appetite, hair loss or thinning, skin rashes, itching, fluid retention, weight gain, elevated body temperature, increased susceptibility to infections, etc.
The rising incidence of blood diseases, including leukemia, lymphoma, multiple myeloma, etc., that cause damage to bone marrow and disrupt normal blood cell production is primarily driving the hematopoietic stem cell transplantation market. In addition to this, the inflating utilization of advanced transplant techniques, such as reduced-intensity conditioning regimens, improved tissue typing and matching, and better depletion of T-cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of gene editing technologies, like CRISPR, which offer the possibility of modifying stem cells to improve their disease-fighting abilities or enhance tolerance to the recipient's immune system, is further bolstering the market growth. Additionally, several government agencies and non-governmental organizations are launching campaigns to raise awareness and increase access to educational programs related to the ailment, including behavioral counseling for patients. This, in turn, is also propelling the market growth. Furthermore, the emerging popularity of next-generation sequencing procedures, which enhance the availability of suitable donors, thereby promoting the adoption of HSCT, is expected to drive the hematopoietic stem cell transplantation market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hematopoietic stem cell transplantation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hematopoietic stem cell transplantation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hematopoietic stem cell transplantation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hematopoietic stem cell transplantation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hematopoietic stem cell transplantation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hematopoietic stem cell transplantation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the hematopoietic stem cell transplantation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hematopoietic stem cell transplantation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hematopoietic stem cell transplantation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation across the seven major markets?
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation by type across the seven major markets?
How many patients are diagnosed (2018-2034) with hematopoietic stem cell transplantation across the seven major markets?
What is the size of the hematopoietic stem cell transplantation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hematopoietic stem cell transplantation?
What will be the growth rate of patients across the seven major markets?
Hematopoietic Stem Cell Transplantation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hematopoietic stem cell transplantation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hematopoietic stem cell transplantation market?
What are the key regulatory events related to the hematopoietic stem cell transplantation market?
What is the structure of clinical trial landscape by status related to the hematopoietic stem cell transplantation market?
What is the structure of clinical trial landscape by phase related to the hematopoietic stem cell transplantation market?
What is the structure of clinical trial landscape by route of administration related to the hematopoietic stem cell transplantation market?
The hematopoietic stem cell transplantation market has been comprehensively analyzed in IMARC's new report titled "Hematopoietic Stem Cell Transplantation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hematopoietic stem cell transplantation (HSCT) refers to a medical procedure used to treat various conditions affecting the blood and immune system. This technique involves the replacement of damaged or destroyed bone marrow with healthy blood cells, including red blood cells, white blood cells, and platelets. It is broadly categorized as autologous, allogeneic, or syngeneic transplantation. Autologous HSCT involves using a patient's own stem cells for transplantation, whereas allogeneic HSCT relies on stem cells obtained from a donor, typically a family member or an unrelated donor with compatible tissue typing. In syngeneic transplantation, the donor and recipient are generally identical twins, although it can also be performed between other individuals who share a close genetic match. Various cell sources include bone marrow, umbilical cord blood, peripheral blood, or, rarely, fetal liver. In some cases, the patients might experience transplantation-related symptoms, such as nausea, vomiting, mouth sores or ulcers, diarrhea, abdominal pain, loss of appetite, hair loss or thinning, skin rashes, itching, fluid retention, weight gain, elevated body temperature, increased susceptibility to infections, etc.
The rising incidence of blood diseases, including leukemia, lymphoma, multiple myeloma, etc., that cause damage to bone marrow and disrupt normal blood cell production is primarily driving the hematopoietic stem cell transplantation market. In addition to this, the inflating utilization of advanced transplant techniques, such as reduced-intensity conditioning regimens, improved tissue typing and matching, and better depletion of T-cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of gene editing technologies, like CRISPR, which offer the possibility of modifying stem cells to improve their disease-fighting abilities or enhance tolerance to the recipient's immune system, is further bolstering the market growth. Additionally, several government agencies and non-governmental organizations are launching campaigns to raise awareness and increase access to educational programs related to the ailment, including behavioral counseling for patients. This, in turn, is also propelling the market growth. Furthermore, the emerging popularity of next-generation sequencing procedures, which enhance the availability of suitable donors, thereby promoting the adoption of HSCT, is expected to drive the hematopoietic stem cell transplantation market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hematopoietic stem cell transplantation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hematopoietic stem cell transplantation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hematopoietic stem cell transplantation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hematopoietic stem cell transplantation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hematopoietic stem cell transplantation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hematopoietic stem cell transplantation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the hematopoietic stem cell transplantation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hematopoietic stem cell transplantation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hematopoietic stem cell transplantation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation across the seven major markets?
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of hematopoietic stem cell transplantation by type across the seven major markets?
How many patients are diagnosed (2018-2034) with hematopoietic stem cell transplantation across the seven major markets?
What is the size of the hematopoietic stem cell transplantation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hematopoietic stem cell transplantation?
What will be the growth rate of patients across the seven major markets?
Hematopoietic Stem Cell Transplantation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hematopoietic stem cell transplantation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hematopoietic stem cell transplantation market?
What are the key regulatory events related to the hematopoietic stem cell transplantation market?
What is the structure of clinical trial landscape by status related to the hematopoietic stem cell transplantation market?
What is the structure of clinical trial landscape by phase related to the hematopoietic stem cell transplantation market?
What is the structure of clinical trial landscape by route of administration related to the hematopoietic stem cell transplantation market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEMATOPOIETIC STEM CELL TRANSPLANTATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEMATOPOIETIC STEM CELL TRANSPLANTATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEMATOPOIETIC STEM CELL TRANSPLANTATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 HEMATOPOIETIC STEM CELL TRANSPLANTATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEMATOPOIETIC STEM CELL TRANSPLANTATION - UNMET NEEDS
10 HEMATOPOIETIC STEM CELL TRANSPLANTATION - KEY ENDPOINTS OF TREATMENT
11 HEMATOPOIETIC STEM CELL TRANSPLANTATION - MARKETED PRODUCTS
11.1 List of Hematopoietic Stem Cell Transplantation Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 HEMATOPOIETIC STEM CELL TRANSPLANTATION - PIPELINE DRUGS
12.1 List of Hematopoietic Stem Cell Transplantation Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. HEMATOPOIETIC STEM CELL TRANSPLANTATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEMATOPOIETIC STEM CELL TRANSPLANTATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEMATOPOIETIC STEM CELL TRANSPLANTATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hematopoietic Stem Cell Transplantation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hematopoietic Stem Cell Transplantation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hematopoietic Stem Cell Transplantation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hematopoietic Stem Cell Transplantation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hematopoietic Stem Cell Transplantation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hematopoietic Stem Cell Transplantation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hematopoietic Stem Cell Transplantation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hematopoietic Stem Cell Transplantation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
16 HEMATOPOIETIC STEM CELL TRANSPLANTATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEMATOPOIETIC STEM CELL TRANSPLANTATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEMATOPOIETIC STEM CELL TRANSPLANTATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEMATOPOIETIC STEM CELL TRANSPLANTATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 HEMATOPOIETIC STEM CELL TRANSPLANTATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEMATOPOIETIC STEM CELL TRANSPLANTATION - UNMET NEEDS
10 HEMATOPOIETIC STEM CELL TRANSPLANTATION - KEY ENDPOINTS OF TREATMENT
11 HEMATOPOIETIC STEM CELL TRANSPLANTATION - MARKETED PRODUCTS
11.1 List of Hematopoietic Stem Cell Transplantation Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 HEMATOPOIETIC STEM CELL TRANSPLANTATION - PIPELINE DRUGS
12.1 List of Hematopoietic Stem Cell Transplantation Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. HEMATOPOIETIC STEM CELL TRANSPLANTATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEMATOPOIETIC STEM CELL TRANSPLANTATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEMATOPOIETIC STEM CELL TRANSPLANTATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hematopoietic Stem Cell Transplantation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hematopoietic Stem Cell Transplantation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hematopoietic Stem Cell Transplantation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hematopoietic Stem Cell Transplantation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hematopoietic Stem Cell Transplantation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hematopoietic Stem Cell Transplantation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hematopoietic Stem Cell Transplantation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hematopoietic Stem Cell Transplantation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hematopoietic Stem Cell Transplantation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hematopoietic Stem Cell Transplantation - Access and Reimbursement Overview
16 HEMATOPOIETIC STEM CELL TRANSPLANTATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
